In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.93.
According to TipRanks, Livnat is an analyst with an average return of -0.5% and a 42.68% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Otonomy, and Collegium Pharmaceutical.
Currently, the analyst consensus on Xeris Pharmaceuticals is a Strong Buy with an average price target of $6.00.
Based on Xeris Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.07 million and a GAAP net loss of $33.71 million. In comparison, last year the company earned a revenue of $8.2 million and had a GAAP net loss of $18.41 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XERS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
- Aadi Bioscience (AADI) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Reaffirms Their Buy Rating on Vaccitech Plc (VACC)
- H.C. Wainwright Keeps Their Buy Rating on Cidara Therapeutics (CDTX)
- H.C. Wainwright Reaffirms Their Buy Rating on Catalyst Pharma (CPRX)
- H.C. Wainwright Sticks to Their Buy Rating for Decibel Therapeutics (DBTX)